Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Pfizer

Bristol Myers' innovative wheel should keep revenue moving in the right direction. Pfizer's success in the coronavirus market is helping fund other potential products.

2 Dirt Cheap Dividend Stocks to Buy Right Now

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.75 per share, missing the Zacks Consensus Estimate of $1.99 per share. This compares to earnings of $1.93 per share a year ago.

Bristol Myers Squibb (BMY) Misses Q2 Earnings and Revenue Estimates

Cancer-fighting drugs Revlimid and Pomalyst drive a sales shortfall in the second quarter.

Bristol Myers Slashes Forecast on Tumbling Revlimid Sales

Shares of Bristol Myers Squibb Co. BMY, -0.56% shed 2.2% in premarket trading Thursday, after the drugmaker missed second-quarter earnings expectations and cut its full-year outlook, amid a more rapid than expected decline in sales of its cancer treatment Revlimid. Net income rose to $2.07 billion, or 99 cents a share, from $1.42 billion, or 66 cents a share, in the year-ago period.

Bristol Myers stock takes a hit from earnings miss and lower outlook amid disappointing Revlimid sales

Drugmaker Bristol Myers Squibb said on Thursday its second-quarter sales fell more than expected and cut its full-year forecast as two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.

Bristol Myers sales fall, cuts 2023 forecast as drugs face competition

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Reports Second Quarter Financial Results for 2023.

Bristol Myers Squibb Reports Second Quarter Financial Results for 2023

Apple

Amgen

Broadcom

Blackrock Inc

Carrier Global

Caterpillar

Chubb

Comcast

Cisco Systems

Dick's Sporting Goods

General Mills

HSBC Holdings

iShares Core S&P 500 ETF

Johnson & Johnson

Juniper Networks

Kellogg

Kroger

Lowe's

Mondelez

Medtronic

Microsoft

QUALCOMM

Invesco QQQ

Invesco S&P 500 Equal Weight ETF

My U.S. dividend growth portfolio, constructed in 2015, has outperformed the market by over 2% annually. The portfolio was designed to be resilient in a major stock market correction, focusing on dividend achievers with at least 10 years of dividend growth. For building a similar portfolio in 2023, I considered valuation and growth, leaning towards larger cap or mega-cap stocks, and factored in retirement income needs.

Building The Dividend Growth Portfolio In 2023

Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results.

Bristol-Myers (BMY) to Report Q2 Earnings: What's in Store?

Many high-yielding stocks are either too risky or too expensive. Amgen and Bristol Myers Squibb offer above-average dividend yields, attractive valuations, and a reasonable margin of safety.

2 Cheap High-Yield Dividend Stocks to Buy Now

Immatics NV

Shares of Immatics N.V. IMTX, +0.08% gained more than 8% premarket on Monday after the clinical-stage biopharma company said it had received a $35 million equity investment from Bristol Myers Squibb Co. BMY, +1.43%.

Immatics shares jump after investment from Bristol Myers Squibb

Bristol-Myers Squibb Company (BMY) is a promising investment opportunity due to its strong presence in oncology and immunology, and its robust pipeline of compounds in development. The stock price of BMY demonstrates a strong bullish trend, suggesting a promising buying opportunity.

Bristol-Myers Squibb Is A Buy At Current Support (Technical Analysis)

Bristol-Myers Squibb is expected to report its Q2 results on July 27, with market sentiments highly pessimistic, heading into its earnings release. The company faces revenue challenges due to the loss of exclusivity for Revlimid. I gleaned that the market has likely reflected significant headwinds on BMY's ability to recover. BMY's sentiments have likely reached peak pessimism, auguring well for its upcoming earnings. Analysts are also pessimistic, lowering the bar for BMY to clear.

Bristol Myers Squibb: The Gift Has Arrived

GlaxoSmithKline

Pharma stocks experienced an abysmal first half due to various factors. Rotation from defensive to cyclical sectors, drug price negotiations and upcoming patent cliffs have muddied the outlook.

The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023

On July 27, 2023, Bristol-Myers Squibb, one of the leaders in the global cancer and immunology therapeutics market, will release its financial report for the second quarter of 2023. In the first half of 2023, the company delighted investors with numerous medicine approvals, some of which could become blockbusters in the next two years. Despite positive clinical results, BMY's share price has declined by over 14% since the start of 2023, underperforming compared to competitors like Sanofi, AstraZeneca, and GSK.

The Bristol-Myers Squibb Phenomenon: A Game Changer In The Pharmaceutical Industry

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) (**see release for complete title**).

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol Myers Squibb (BMY) Earnings Expected to Grow: Should You Buy?

Greed has gripped the market, but that doesn't mean you can't invest wisely. Even today, anti-bubble blue-chip bargains like Bristol-Myers Squibb Company are hitting new 52-week lows. Bristol-Myers is an A+ rated 3.7% yielding pharma titan with a strong pipeline, rivers of free cash flow, and the 7th largest pharma R&D budget in the world.

Bristol-Myers: Potentially Set To Soar And Too Cheap To Ignore

AbbVie

Arbor Realty Trust

Abbott Labs

Archer-Daniels-Midland Company

Aflac

Ameriprise Financial

Amazon

American Express

Bank of America

Becton, Dickinson and Co.

Citigroup

Cardinal Health

CVS Health

Chevron

Disney

Digital Realty Trust

Duke Energy

Emerson Electric

Enterprise Products Partners

Eaton

In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing. This article summarizes Q2 of 2023 and focuses on goals, current holdings, allocation, sales, and buys.

My Dividend Growth Portfolio - Q2 2023 Summary

Bristol Myers Squibb (BMY) closed at $62.28 in the latest trading session, marking no change from the prior day.

Bristol Myers Squibb (BMY) Flat As Market Gains: What You Should Know

Merck

The U.S. Chamber of Commerce asked a judge to stop the federal government from putting into effect a law that will allow Medicare to negotiate the prices of some prescription drugs.

Big Pharma Ramps Up Fight Against Medicare Price Negotiations

Domino's Pizza

The S&P 500 and Nasdaq saw a significant rally in the first half of 2023, led by technology companies, with the top three performing sectors being Information Technology, Communication Services, and Consumer Discretionary. Given the top heavy rally in the first half, we go value hunting in today's piece and look at three quality dividend stocks primed to outperform in the second half. There is a lot of uncertainty in the back half of the year, which could have investors switch from risk-on assets to more defensive sectors.

3 Dividend Stocks Poised To Outperform The Rest Of 2023

Bristol Myers (BMY) meets its dual primary endpoint in the late-stage expansion study of Opdivo for the treatment of unresectable or metastatic urothelial carcinoma.

Bristol Myers (BMY) Reports Positive Data From Urothelial Cancer Study

Bristol-Myers Squibb Co said on Tuesday its drug in combination with chemotherapy met a dual main goal in a late-stage trial in patients with a type of bladder cancer.

Bristol Myers' bladder cancer drug meets goal in late stage sub-study

News for Bristol-Myers Stock (BMY)